Lifecome Biochemistry (002868.SZ) expects a pre-loss, with a projected net loss of 340-390 million yuan in 2024, an increase in losses compared to the previous year.
Lukang Pharmaceutical (002868.SZ) announced that it is expected to incur a net loss of 30 million yuan attributable to the shareholders of the listed company in 2024.
Lifecome Biochemistry (002868.SZ) announced that it expects a net loss attributable to shareholders of the listed company of 340 million to 390 million yuan in 2024, with a year-on-year increase in losses. It is also expected that the net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, will be 345 million to 395 million yuan, with an expanded year-on-year loss.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
